1. Anti-infection
  2. HBV


HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

HBV Related Products (19):

Cat. No. Product Name Effect Purity
  • HY-13782
    Tenofovir Disoproxil Fumarate Inhibitor 99.38%
    Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.
  • HY-16468
    Squalamine Inhibitor >98.0%
    Squalamine(MSI-1256) is an aminosterol compound with potent broad spectrum antiviral activity.
  • HY-13986
    Merimepodib Inhibitor 98.22%
    Merimepodib is a novel noncompetitive inhibitor of IMPDH (Inosine monophosphate dehydrogenase).
  • HY-100029
    Bay 41-4109 Inhibitor 98.92%
    BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.
  • HY-13623A
    Entecavir monohydrate Inhibitor 99.66%
    Entecavir monohydrate (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC50 of 3.75 nM in HepG2 cell.
  • HY-107902
    RIG-1 modulator 1 Inhibitor
    RIG-1 modulator 1 is an anti-viral compound which can be useful for the treatment of viral infections including influenza virus, HBV, HCV and HIV extracted from patent WO 2015172099 A1.
  • HY-B0255
    Adefovir dipivoxil Inhibitor 98.50%
    Adefovir Dipivoxil works by blocking reverse transcriptase, an enzyme that is crucial for the hepatitis B virus (HBV) to reproduce in the body.
  • HY-13623
    Entecavir Inhibitor 98.88%
    Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC50 of 3.75 nM in HepG2 cell.
  • HY-13859
    Clevudine Inhibitor >98.0%
    Clevudine is an antiviral drug for the treatment of hepatitis B.
  • HY-100029A
    Bay 41-4109 racemate Inhibitor 98.02%
    BAY 41-4109 racemate is the racemate of BAY 41-4109.
  • HY-B0766
    Bicyclol Inhibitor 99.57%
    Bicyclol(SY 801) is a anti-hepatitis drug.
  • HY-B0017
    Telbivudine Inhibitor 99.52%
    Telbivudine, a specific inhibitor of hepatitis B virus (HBV) replication, is an antiviral drug used in the treatment of hepatitis B infection.
  • HY-B2116
    Osalmid Inhibitor 99.80%
    Osalmid is a ribonucleotide reductase small subunit M2 (RRM2) targeting compound; suppresses ribonucleotide reductase activity with an IC50 of 8.23 μM.
  • HY-13782A
    Tenofovir Disoproxil Inhibitor >98.0%
    Tenofovir dsoproxil is an antiretroviral agent used to prevent and treat HIV/AIDS and to treat chronic hepatitis B.
  • HY-100029B
    Bay 41-4109 less active enantiomer Inhibitor
    Bay 41-4109 less active enantiomer shows less activity than Bay 41-4109.
  • HY-16680
    Helioxanthin 8-1 Inhibitor
    Helioxanthin 8-1 is an analogue of helioxanthin, exhibites significant in vitro anti-HBV/HCV/HSV-1/HIV activity with EC50 of >5/10/1.4/15 uM.
  • HY-16679
    Helioxanthin derivative 5-4-2 Inhibitor 99.76%
    Helioxanthin derivative 5-4-2 is an analogue of helioxanthin, exhibites significant in vitro anti-HBV activity with EC50 of 0.08 uM in HepG2.2.15 cells.
  • HY-B0955
    Oxethazaine Inhibitor 99.86%
    Oxethazaine is a topical anesthetic, in preventing acid-induced esophageal pain.
  • HY-14844
    Lagociclovir Inhibitor
    Lagociclovir(MIV-210) is a prodrug of 3'-fluoro-2',3'-dideoxyguanosine with high oral bioavailability in humans and potent activity against HBV.